全文获取类型
收费全文 | 39112篇 |
免费 | 7502篇 |
国内免费 | 145篇 |
专业分类
耳鼻咽喉 | 781篇 |
儿科学 | 1267篇 |
妇产科学 | 1005篇 |
基础医学 | 2825篇 |
口腔科学 | 2988篇 |
临床医学 | 6057篇 |
内科学 | 8430篇 |
皮肤病学 | 901篇 |
神经病学 | 3501篇 |
特种医学 | 1547篇 |
外国民族医学 | 11篇 |
外科学 | 5701篇 |
综合类 | 358篇 |
现状与发展 | 12篇 |
一般理论 | 25篇 |
预防医学 | 4669篇 |
眼科学 | 1050篇 |
药学 | 1664篇 |
中国医学 | 17篇 |
肿瘤学 | 3950篇 |
出版年
2023年 | 1142篇 |
2022年 | 454篇 |
2021年 | 880篇 |
2020年 | 1353篇 |
2019年 | 785篇 |
2018年 | 1612篇 |
2017年 | 1488篇 |
2016年 | 1740篇 |
2015年 | 1856篇 |
2014年 | 2352篇 |
2013年 | 2937篇 |
2012年 | 1554篇 |
2011年 | 1580篇 |
2010年 | 1805篇 |
2009年 | 2349篇 |
2008年 | 1424篇 |
2007年 | 1188篇 |
2006年 | 1347篇 |
2005年 | 1169篇 |
2004年 | 1061篇 |
2003年 | 942篇 |
2002年 | 873篇 |
2001年 | 1003篇 |
2000年 | 940篇 |
1999年 | 899篇 |
1998年 | 698篇 |
1997年 | 669篇 |
1996年 | 701篇 |
1995年 | 568篇 |
1994年 | 450篇 |
1993年 | 412篇 |
1992年 | 595篇 |
1991年 | 573篇 |
1990年 | 544篇 |
1989年 | 551篇 |
1988年 | 480篇 |
1987年 | 531篇 |
1986年 | 433篇 |
1985年 | 444篇 |
1984年 | 358篇 |
1983年 | 350篇 |
1982年 | 234篇 |
1981年 | 221篇 |
1980年 | 197篇 |
1979年 | 310篇 |
1978年 | 250篇 |
1977年 | 197篇 |
1976年 | 190篇 |
1975年 | 189篇 |
1974年 | 206篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
991.
992.
Shih-Chieh Shao MS Kai-Cheng Chang MS Rong-Nan Chien MD Swu-Jane Lin PhD Ming-Jui Hung MD Yuk-Ying Chan MS Yea-Huei Kao Yang BPharm Edward Chia-Cheng Lai PhD 《Diabetes, obesity & metabolism》2020,22(1):128-134
Clinical trials have indicated that sodium-glucose co-transporter-2 (SGLT2) inhibitors have a favourable effect on serum alanine aminotransferase (ALT) levels in people with type 2 diabetes (T2D), but supporting evidence from real-world studies is lacking. We identified patients with T2D who initiated SGLT2 inhibitors during the period 2016 to 2017 from Chang Gung Research Database, which covers 1.3 million individuals from seven hospitals (6% of the Taiwan population). We classified patients by baseline ALT level and evaluated changes in ALT values from baseline to 1 year after initiation of SGLT2 inhibitors. We identified 11 690 new users of SGLT2 inhibitors with a mean (SD) age of 59.3 (11.8) years. The mean (SD) glycated haemoglobin and ALT levels were 8.9 (1.7)% and 34.7 (28.9) U/L at baseline, respectively. The mean change in ALT levels was −5.0 U/L (95% confidence interval [CI] –6.4, −3.5) 1 year after initiation of SGLT2 inhibitors. In patients with ALT levels ≤1× the upper limit of normal (ULN), the change in ALT levels was 1.6 U/L (95% CI –0.1, 3.4), while in those with ALT levels >1× ULN, the change in ALT levels was −26.5 U/L (95% CI –28.6, −24.3). The higher the baseline ALT level, the greater the decline after SGLT2 inhibitor treatment. Our findings suggest the initiation of SGLT2 inhibitors for T2D management could improve serum ALT levels in clinical practice, particularly in patients with especially high ALT levels. 相似文献
993.
994.
Shweta Urva PhD Tamer Coskun MD Corina Loghin MD Xuewei Cui PhD Emily Beebe BS Libbey O'Farrell BS Daniel A. Briere MS Charles Benson MD Michael A. Nauck MD Axel Haupt MD 《Diabetes, obesity & metabolism》2020,22(10):1886-1891
The effect of dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist (RA) tirzepatide on gastric emptying (GE) was compared to that of GLP-1RAs in non-clinical and clinical studies. GE was assessed following acute and chronic treatment with tirzepatide in diet-induced obese mice versus semaglutide or long-acting GIP analogue alone. Participants [with and without type 2 diabetes (T2DM)] from a phase 1, 4-week multiple dose study received tirzepatide, dulaglutide or placebo. GE was assessed by acetaminophen absorption. In mice, tirzepatide delayed GE to a similar degree to that achieved with semaglutide; however, these acute inhibitory effects were abolished after 2 weeks of treatment. GIP analogue alone had no effect on GE or on GLP-1's effect on GE. In participants with and without T2DM, once-weekly tirzepatide (≥5 and ≥4.5 mg, respectively) delayed GE after a single dose. This effect diminished after multiple doses of tirzepatide or dulaglutide in healthy participants. In participants with T2DM treated with an escalation schedule of tirzepatide 5/5/10/10 or 5/5/10/15 mg, a residual GE delay was still observed after multiple doses. These data suggest that tirzepatide's activity on GE is comparable to that of selective GLP-1RAs. 相似文献
995.
996.
997.
998.
999.
Fernanda Leite de Souza Franceschi Jaime Green Zuzan Cayci Evan Mariash Mustapha Ezzeddine Veronika Bachanova Celalettin Ustun 《The Canadian Journal of Infectious Diseases & Medical Microbiology》2014,25(3):170-172
Status epilepticus after allogeneic hematopoietic cell transplantation (alloHCT) is rare. The authors report a case involving a 65-year-old man with nonconvulsive status epilepticus 34 days after umbilical cord blood transplantion for chronic lymphocytic leukemia. Cerebrospinal fluid and serum were positive for human herpesvirus 6 (HHV6). Magnetic resonance imaging of the brain showed symmetric T2 hyper-intensity bilaterally in the mesial temporal lobes, and T2 hyperintensi-ties and restricted diffusion of bilateral putamina. Despite aggressive anticonvulsive therapy, his seizures only abated with initiation of ganciclovir therapy. The patient completed six weeks of combination antiviral therapy (ganciclovir and foscarnet). His cognitive function gradually improved and, after prolonged rehabilitation, the patient was discharged home with residual intermittent memory loss but otherwise functional. HHV6 should be considered in the differential diagnosis of nonconvulsive status epilepticus after alloHCT, especially in patients with hyponatremia. Empirical antiviral therapy targeting HHV6 should be administered to these patients. 相似文献
1000.